A novel fusion of TPR and ALK in lung adenocarcinoma - PubMed (original) (raw)
Case Reports
doi: 10.1097/JTO.0000000000000093.
Maruja E Lira, Mineui Hong, Ryong Nam Kim, So-Jung Choi, Ji-Young Song, Kinnari Pandy, Derrick L Mann, Joshua A Stahl, Heather E Peckham, Zongli Zheng, Joungho Han, Mao Mao, Jhingook Kim
Affiliations
- PMID: 24736082
- DOI: 10.1097/JTO.0000000000000093
Free article
Case Reports
A novel fusion of TPR and ALK in lung adenocarcinoma
Yoon-La Choi et al. J Thorac Oncol. 2014 Apr.
Free article
Abstract
Introduction: Anaplastic lymphoma kinase (ALK) fusion is the most common mechanism for overexpression and activation in non-small-cell lung carcinoma. Several fusion partners of ALK have been reported, including echinoderm microtubule-associated protein-like 4, TRK-fused gene, kinesin family member 5B, kinesin light chain 1 (KLC1), protein tyrosine phosphatase and nonreceptor type 3, and huntingtin interacting protein 1 (HIP1).
Methods and results: A 60-year-old Korean man had a lung mass which was a poorly differentiated adenocarcinoma with ALK overexpression. By using an Anchored Multiplex polymerase chain reaction assay and sequencing, we found that tumor had a novel translocated promoter region (TPR)-ALK fusion. The fusion transcript was generated from an intact, in-frame fusion of TPR exon 15 and ALK exon 20 (t(1;2)(q31.1;p23)). The TPR-ALK fusion encodes a predicted protein of 1192 amino acids with a coiled-coil domain encoded by the 5'-2 of the TPR and juxtamembrane and kinase domains encoded by the 3'-end of the ALK.
Conclusions: The novel fusion gene and its protein TRP-ALK, harboring coiled-coil and kinase domains, could possess transforming potential and responses to treatment with ALK inhibitors. This case is the first report of TPR-ALK fusion transcript in clinical tumor samples and could provide a novel diagnostic and therapeutic candidate target for patients with cancer, including non-small-cell lung carcinoma.
Similar articles
- HIP1-ALK, a novel fusion protein identified in lung adenocarcinoma.
Hong M, Kim RN, Song JY, Choi SJ, Oh E, Lira ME, Mao M, Takeuchi K, Han J, Kim J, Choi YL. Hong M, et al. J Thorac Oncol. 2014 Mar;9(3):419-22. doi: 10.1097/JTO.0000000000000061. J Thorac Oncol. 2014. PMID: 24518094 - EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.
Wu SG, Kuo YW, Chang YL, Shih JY, Chen YH, Tsai MF, Yu CJ, Yang CH, Yang PC. Wu SG, et al. J Thorac Oncol. 2012 Jan;7(1):98-104. doi: 10.1097/JTO.0b013e3182370e30. J Thorac Oncol. 2012. PMID: 22124476 - SEC31A-ALK Fusion Gene in Lung Adenocarcinoma.
Kim RN, Choi YL, Lee MS, Lira ME, Mao M, Mann D, Stahl J, Licon A, Choi SJ, Van Vrancken M, Han J, Wlodarska I, Kim J. Kim RN, et al. Cancer Res Treat. 2016 Jan;48(1):398-402. doi: 10.4143/crt.2014.254. Epub 2015 Feb 17. Cancer Res Treat. 2016. PMID: 25715771 Free PMC article. - Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
Toyokawa G, Seto T. Toyokawa G, et al. Respir Investig. 2014 Nov;52(6):330-8. doi: 10.1016/j.resinv.2014.06.005. Epub 2014 Jul 30. Respir Investig. 2014. PMID: 25453376 Review. - RANBP2-ALK fusion combined with monosomy 7 in acute myelomonocytic leukemia.
Lim JH, Jang S, Park CJ, Cho YU, Lee JH, Lee KH, Lee JO, Shin JY, Kim JI, Huh J, Seo EJ. Lim JH, et al. Cancer Genet. 2014 Jan-Feb;207(1-2):40-5. doi: 10.1016/j.cancergen.2013.12.003. Epub 2014 Jan 21. Cancer Genet. 2014. PMID: 24613277 Review.
Cited by
- Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening.
Lee J, Kim HC, Hong JY, Wang K, Kim SY, Jang J, Kim ST, Park JO, Lim HY, Kang WK, Park YS, Lee J, Lee WY, Park YA, Huh JW, Yun SH, Do IG, Kim SH, Balasubramanian S, Stephens PJ, Ross JS, Li GG, Hornby Z, Ali SM, Miller VA, Kim KM, Ou SH. Lee J, et al. Oncotarget. 2015 Sep 15;6(27):24320-32. doi: 10.18632/oncotarget.4462. Oncotarget. 2015. PMID: 26172300 Free PMC article. - Application of Super-resolution SPEED Microscopy in the Study of Cellular Dynamics.
Yu W, Rush C, Tingey M, Junod S, Yang W. Yu W, et al. Chem Biomed Imaging. 2023 Jun 24;1(4):356-371. doi: 10.1021/cbmi.3c00036. eCollection 2023 Jul 24. Chem Biomed Imaging. 2023. PMID: 37501792 Free PMC article. Review. - Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes.
Sharma GG, Mota I, Mologni L, Patrucco E, Gambacorti-Passerini C, Chiarle R. Sharma GG, et al. Cancers (Basel). 2018 Feb 28;10(3):62. doi: 10.3390/cancers10030062. Cancers (Basel). 2018. PMID: 29495603 Free PMC article. Review. - Targeting ALK: Precision Medicine Takes on Drug Resistance.
Lin JJ, Riely GJ, Shaw AT. Lin JJ, et al. Cancer Discov. 2017 Feb;7(2):137-155. doi: 10.1158/2159-8290.CD-16-1123. Epub 2017 Jan 25. Cancer Discov. 2017. PMID: 28122866 Free PMC article. Review. - Anaplastic lymphoma kinase fusions: Roles in cancer and therapeutic perspectives.
Cao Z, Gao Q, Fu M, Ni N, Pei Y, Ou WB. Cao Z, et al. Oncol Lett. 2019 Feb;17(2):2020-2030. doi: 10.3892/ol.2018.9856. Epub 2018 Dec 20. Oncol Lett. 2019. PMID: 30675269 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous